COVID-19 vaccine hesitancy in Latin America and Africa: a scoping review

Imagem de Miniatura
Arquivos
art_GONCALVES_COVID19_vaccine_hesitancy_in_Latin_America_and_Africa_2023_por.PDF (1.19 MB)
art_GONCALVES_COVID19_vaccine_hesitancy_in_Latin_America_and_Africa_2023_eng.PDF (1.14 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CADERNOS SAUDE PUBLICA
Autores
Citação
CADERNOS DE SAUDE PUBLICA, v.39, n.8, p.1-26, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Vaccination has played an important role in the containment of COVID-19 pandemic advances. However, SARS-CoV-2 vaccine hesitancy has caused a global concern. This scoping review aims to map the scientific literature on COVID-19 vaccine hesitancy in Latin America and Africa from a Global Health perspective, observing the particularities of the Global South and using parameters validated by the World Health Organization (WHO). The review reporting observes the recommendations of the PRISMA for Scoping Reviews (PRISMA-ScR) model. Search was conducted in PubMed, Scopus, Web of Science, and Virtual Health Library (VHL) databases, selecting studies published from January 1, 2020 to January 22, 2022. Selected studies indicate that COVID-19 vaccine hesitancy involves factors such as political scenario, spread of misinformation, regional differences in each territory regarding Internet access, lack of access to information, history of vaccination resistance, lack of information about the disease and the vaccine, concern about adverse events, and vaccine efficacy and safety. Regarding the use of conceptual and methodology references from the WHO for vaccine hesitancy, few studies (6/94) use research instruments based on these references. Then, the replication in Global South of conceptual and methodological parameters developed by experts from the Global North contexts has been criticized from the perspective of Global Health because of it may not consider political and sociocultural particularities, the different nuances of vaccine hesitancy, and issues of access to vaccines.
A vacinação tem papel relevante para conter os avanços da pandemia de COVID-19. No entanto, a hesitação vacinal com os imunizantes que agem contra o SARS-CoV-2 tem causado preocupação em âmbito global. Esta revisão de escopo tem como objetivo mapear a literatura científica sobre a hesitação vacinal contra a COVID-19 na América Latina e África sob uma perspectiva da Saúde Global, observando as particularidades do Sul Global e o uso de parâmetros validados pela Organização Mundial da Saúde (OMS). O relato da revisão segue as recomendações do protocolo PRISMA para Revisões de Escopo (PRISMA-ScR). O levantamento foi realizado nas bases de dados PubMed, Scopus, Web of Science e Biblioteca Virtual em Saúde (BVS), selecionando estudos publicados entre 1º de janeiro de 2020 e 22 de janeiro de 2022, os quais indicam que a hesitação vacinal contra a COVID-19 envolve fatores como o cenário político, a disseminação de desinformação, diferenças regionais referentes ao acesso à Internet, falta de acesso à informação, o histórico de resistência à vacinação, falta de informações sobre a doença e a vacina, preocupação com eventos adversos, eficácia e segurança dos imunizantes. Quanto ao uso dos referenciais conceituais e metodológicos da OMS sobre hesitação vacinal, poucos estudos (apenas 6 de 94) utilizam instrumentos de pesquisa baseado neles. Desta forma, a replicação de parâmetros conceituais e metodológicos elaborados por expertises do Norte Global em contextos do Sul Global tem sido criticada pela perspectiva da Saúde Global, em decorrência da possibilidade de não considerar as especificidades políticas e socioculturais, as diferentes nuances de hesitação vacinal e questões de acesso às vacinas.
La vacunación tiene un papel relevante para frenar los avances de la pandemia de COVID-19. Sin embargo, la indecisión a las vacunas contra el SARS-CoV-2 ha causado preocupación a nivel global. Esta revisión de alcance tiene como objetivo mapear la literatura científica sobre la indecisión a las vacunas contra COVID-19 en América Latina y África desde una perspectiva de la Salud Global, observando las particularidades del Sur Global y el uso de parámetros validados por la Organización Mundial de la Salud (OMS). El informe de la revisión sigue las recomendaciones del protocolo PRISMA para Revisiones de Alcance (PRISMA-ScR). La encuesta se realizó en las bases de datos PubMed, Scopus, Web of Science e Biblioteca Virtual en Salud (BVS), seleccionando los estudios publicados entre 1º de enero de 2020 y 22 de enero de 2022. Los estudios seleccionados indican que la indecisión a las vacunas de COVID-19 involucra factores como el escenario político, la diseminación de desinformación, las diferencias regionales de cada territorio referente al acceso a Internet, la falta de acceso a la información, el historial de resistencia a la vacunación, la falta de informaciones sobre la enfermedad y la vacuna, la preocupación por los eventos adversos, la eficacia y la seguridad de los inmunizantes. En cuanto al uso de los referenciales conceptuales y metodológicos de la Organización Mundial de la Salud (OMS) sobre la indecisión a las vacunas, pocos estudios (6/94) utilizan instrumentos de investigación basados en esos referenciales. Así, la replicación de parámetros conceptuales y metodológicos elaborados por expertos del Norte Global en contextos del Sur Global ha sido criticada por la perspectiva de la Salud Global, por la posibilidad de no considerar las especificidades políticas y socioculturales, los diferentes matices de la indecisión a las vacunas y cuestiones de acceso a las vacunas.
Palavras-chave
Vaccination Hesitancy, COVID-19 Vaccines, Global Health, Saúde Global, Vacilación a la Vacunación, Vacunas Contra la COVID-19, Salud Global
URI
https://observatorio.fm.usp.br/handle/OPI/56165
Referências
  1. Abakar MF, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0873-2
  2. Abdou MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0260321
  3. Acheampong T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080814
  4. Adams V, 2014, MED ANTHROPOL, V33, P179, DOI 10.1080/01459740.2013.858335
  5. Addo PC, 2021, HUM VACC IMMUNOTHER, V17, P5063, DOI 10.1080/21645515.2021.2008729
  6. Adebisi YA, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.230.27325
  7. Adejumo OA, 2021, OSONG PUBLIC HEALTH, V12, P236, DOI 10.24171/j.phrp.2021.0023
  8. Adeniyi OV, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060666
  9. Adigwe OP, 2021, VACCINE-X, V9, DOI 10.1016/j.jvacx.2021.100112
  10. Aemro A, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821002259
  11. Agha S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101162
  12. Dubé É, 2021, ANNU REV PUBL HEALTH, V42, P175, DOI 10.1146/annurev-publhealth-090419-102240
  13. MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
  14. Dula J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080828
  15. Dzinamarira T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030250
  16. Peters MDJ, 2015, INT J EVID-BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050
  17. El-Sokkary RH, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06392-1
  18. Elhadi M, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10987-3
  19. Elsayed M, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10010020
  20. Jaramillo-Monge J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060678
  21. Fares Samar, 2021, J Prim Care Community Health, V12, p21501327211013303, DOI 10.1177/21501327211013303
  22. Mejri N, 2022, SUPPORT CARE CANCER, V30, P289, DOI 10.1007/s00520-021-06419-y
  23. Farouk ZL, 2019, J TROP PEDIATRICS, V65, P569, DOI 10.1093/tropej/fmz012
  24. Gbeasor-Komlanvi F A, 2021, Public Health Pract (Oxf), V2, P100220, DOI 10.1016/j.puhip.2021.100220
  25. Seboka BT, 2021, RISK MANAG HEALTHC P, V14, P2743, DOI 10.2147/RMHP.S315043
  26. Gerede R, 2017, J RELIG HEALTH, V56, P1692, DOI 10.1007/s10943-017-0435-8
  27. Harapan H, 2022, PATHOG GLOB HEALTH, V116, P236, DOI 10.1080/20477724.2021.2011580
  28. Heyerdahl LW, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4072-6
  29. Kpanake L, 2018, HUM VACC IMMUNOTHER, V14, P2391, DOI 10.1080/21645515.2018.1480236
  30. Hochman G, 2011, CIENC SAUDE COLETIVA, V16, P375, DOI 10.1590/S1413-81232011000200002
  31. Horton R, 2020, LANCET, V396, P874, DOI 10.1016/S0140-6736(20)32000-6
  32. Iliyasu Z, 2022, CURR HIV RES, V20, P82, DOI 10.2174/1570162X19666211217093223
  33. Tagoe ET, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.709127
  34. Iliyasu Z, 2022, PATHOG GLOB HEALTH, V116, P254, DOI 10.1080/20477724.2021.2011674
  35. Baeza-Rivera MJ, 2021, J PAC RIM PSYCHOL, V15, DOI 10.1177/18344909211051799
  36. Kanyanda S, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-055159
  37. Machekanyanga Z, 2017, J RELIG HEALTH, V56, P1683, DOI 10.1007/s10943-017-0428-7
  38. Kanyike AM, 2021, TROP MED HEALTH, V49, DOI 10.1186/s41182-021-00331-1
  39. Kassaw C, 2021, VACCINE-X, V9, DOI 10.1016/j.jvacx.2021.100120
  40. Khalis M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9121451
  41. Khalis M, 2021, HUM VACC IMMUNOTHER, V17, P5076, DOI 10.1080/21645515.2021.1989921
  42. Lamptey E, 2021, CLIN EXP VACCINE RES, V10, P183, DOI 10.7774/cevr.2021.10.2.183
  43. Oliveira BLCA, 2021, REV SAUDE PUBL, V55, P12
  44. Mesele M, 2021, INFECT DRUG RESIST, V14, P2361, DOI 10.2147/IDR.S320771
  45. Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
  46. Lazarus JV, 2020, J HEALTH COMMUN, V25, P799, DOI 10.1080/10810730.2020.1868630
  47. Lima-Costa Maria Fernanda, 2022, Epidemiol Serv Saude, V31, pe2021469, DOI 10.1590/S1679-49742022000100020
  48. Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
  49. Macinko J, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-049928
  50. Ticona JPA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090951
  51. Madhi SA, 2018, HUM VACC IMMUNOTHER, V14, P2335, DOI 10.1080/21645515.2018.1522921
  52. Majid U, 2022, HEALTH PROMOT INT, V37, DOI 10.1093/heapro/daac078
  53. Mangla S, 2021, BEHAV SCI-BASEL, V11, DOI 10.3390/bs11110148
  54. Omar DI, 2021, J INFECT PUBLIC HEAL, V14, P1481, DOI 10.1016/j.jiph.2021.06.019
  55. Mohammed R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0261125
  56. Andrade G, 2021, VACCINE, V39, P6837, DOI 10.1016/j.vaccine.2021.10.037
  57. Moore DCBC, 2021, VACCINE, V39, P6262, DOI 10.1016/j.vaccine.2021.09.013
  58. Morhason-Bello IO, 2015, J OBSTET GYNAECOL RE, V41, P1621, DOI 10.1111/jog.12775
  59. Mose A, 2021, INFECT DRUG RESIST, V14, P4249, DOI 10.2147/IDR.S336486
  60. Plotkin SA., 2017, PLOTKINS VACCINES, V7th
  61. Mose A, 2021, INT J GEN MED, V14, P2385, DOI 10.2147/IJGM.S314346
  62. Rezende RPV, 2021, VACCINE, V39, P6454, DOI 10.1016/j.vaccine.2021.09.057
  63. Moulin Anne Marie, 2003, Hist. cienc. saude-Manguinhos, V10, P499, DOI 10.1590/S0104-59702003000500004
  64. Mustapha M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0260672
  65. Berihun G, 2021, PATIENT PREFER ADHER, V15, P1795, DOI 10.2147/PPA.S324564
  66. Oduwole EO, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111246
  67. Orangi S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080936
  68. Organizacao Pan-Americana da Saude, 2018, REL 30 AN SUS QUE SU
  69. Shehata WM, 2022, ENVIRON SCI POLLUT R, V29, P15838, DOI 10.1007/s11356-021-16574-8
  70. Ortega Francisco, 2020, Physis, V30, pe300205, DOI 10.1590/s0103-73312020300205
  71. Oyekale AS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111359
  72. Oyekale AS, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18178892
  73. Bussink-Voorend D, 2022, NAT HUM BEHAV, V6, P1634, DOI 10.1038/s41562-022-01431-6
  74. Peretti-Watel Patrick, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289
  75. Pugliese-Garcia M, 2018, VACCINE, V36, P5617, DOI [10.1016/j.vaccine.2018.07.042, 10.1016/j.vaccine.2017.10.108]
  76. Qunaibi E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050446
  77. Taye BT, 2021, CLIN EPIDEMIOL GLOB, V12, DOI 10.1016/j.cegh.2021.100848
  78. Montenegro CR, 2020, CRIT PUBLIC HEALTH, V30, P127, DOI 10.1080/09581596.2020.1730570
  79. Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378
  80. Rodriguez M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090994
  81. Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910
  82. Shiferie F, 2021, PAN AFR MED J, V40, DOI 10.11604/pamj.2021.40.213.30699
  83. Agyekum MW, 2021, ADV PUBLIC HLTH, V2021, DOI 10.1155/2021/9998176
  84. Vignier N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060682
  85. Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300
  86. Stojanovic J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060661
  87. Streefland P, 1999, SOC SCI MED, V49, P1705, DOI 10.1016/S0277-9536(99)00239-7
  88. Tadele Admasu Fitalew, 2021, Infect Drug Resist, V14, P4865, DOI 10.2147/IDR.S340324
  89. Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
  90. Andrade G, 2021, HUM VACC IMMUNOTHER, V17, P5162, DOI 10.1080/21645515.2021.1981737
  91. Turiho Andrew Kampikaho, 2017, BMC Res Notes, V10, P431, DOI 10.1186/s13104-017-2749-8
  92. Uzochukwu IC, 2021, THER ADV INFECT DIS, V8, DOI 10.1177/20499361211054923
  93. van Prooijen J-W, 2019, BELIEF SYSTEMS PERCE, P79
  94. Ahmed MAM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060543
  95. Vizcardo D, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10010048
  96. Gramacho WG, 2021, VACCINE, V39, P2608, DOI 10.1016/j.vaccine.2021.03.080
  97. Wiyeh AB, 2019, VACCINE, V37, P6317, DOI 10.1016/j.vaccine.2019.09.019
  98. Wiysonge CS, 2022, EXPERT REV VACCINES, V21, P549, DOI 10.1080/14760584.2022.2023355
  99. World Health Organization, 2014, REP SAG WORK GROUP V
  100. Angelo AT, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257109
  101. World Health Organization (WHO), 2022, BEH SOC DRIV VACC TO
  102. Démolis R, 2018, VACCINE, V36, P6497, DOI 10.1016/j.vaccine.2017.10.087
  103. Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8
  104. Yeboah P, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph182412902
  105. Iliyasu Z, 2021, HUM VACC IMMUNOTHER, V17, P4057, DOI 10.1080/21645515.2021.1974796
  106. Zewude B, 2021, INFECT DRUG RESIST, V14, P3071, DOI 10.2147/IDR.S326055
  107. Alhassan RK, 2021, TROP MED HEALTH, V49, DOI 10.1186/s41182-021-00357-5
  108. Alhassan RK, 2021, HUM RESOUR HEALTH, V19, DOI 10.1186/s12960-021-00657-1
  109. Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601
  110. Alle Yewlsew Fentie, 2021, VirusDisease, V32, P272, DOI 10.1007/s13337-021-00708-0
  111. Alvarado-Socarras JL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030287
  112. Amuzie CI, 2021, PAN AFR MED J, V40, DOI 10.11604/pamj.2021.40.10.29816
  113. Khiari Houyem, 2021, Asian Pac J Cancer Prev, V22, P3499, DOI 10.31557/APJCP.2021.22.11.3499
  114. Andrade G, 2022, Vacunas, V23, pS22, DOI 10.1016/j.vacun.2021.07.009
  115. Anjorin AA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0260575
  116. Anorue LI, 2021, INFECT DRUG RESIST, V14, P3785, DOI 10.2147/IDR.S329183
  117. Carcelen AC, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1948784
  118. Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y
  119. Aw J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080900
  120. Bagateli LE, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101115
  121. Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004
  122. Biehl Joao, 2013, PEOPLE COME 1 CRITIC
  123. Biswas MR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111243
  124. Demuyakor J, 2021, ONLINE J COMMUN MEDI, V11, DOI 10.30935/ojcmt/11200
  125. Blanchet K, 2021, CONFL HEALTH, V15, DOI 10.1186/s13031-021-00404-2
  126. Bongomin F, 2021, THER ADV INFECT DIS, V8, DOI 10.1177/20499361211024376
  127. Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515
  128. Botwe BO, 2022, RADIOGRAPHY, V28, P537, DOI 10.1016/j.radi.2021.09.015
  129. Paschoalotto MAC, 2021, REV SAUDE PUBL, V55, DOI 10.11606/s1518-8787.2021055003903
  130. Guzman-Holst A, 2020, VACCINE, V38, P470, DOI 10.1016/j.vaccine.2019.10.088
  131. Cerda AA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.626852
  132. Chinawa AT, 2021, HUM VACC IMMUNOTHER, V17, P3982, DOI 10.1080/21645515.2021.1963172
  133. Chaves IED, 2021, REV ASSOC MED BRAS, V67, P1397, DOI 10.1590/1806-9282.20210379
  134. Matos CCDA, 2022, GLOB PUBLIC HEALTH, V17, P1087, DOI 10.1080/17441692.2021.1912138
  135. Dinga JN, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020175
  136. Okafor UG, 2021, PAN AFR MED J, V40, DOI 10.11604/pamj.2021.40.112.27780
  137. Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153
  138. Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046
  139. Douine M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111216
  140. Handy LK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180759

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/38
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/09